Genmark Diagnostics Inc Revenue Growth Rates (GNMK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Genmark Diagnostics Inc   (NASDAQ: GNMK)
 

GNMK's Revenue Growth by Quarter and Year

Genmark Diagnostics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNMK Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December 50.08
3rd Quarter September 42.65
2nd Quarter June 40.09
1st Quarter March 38.74
FY 171.56

GNMKs Annual Revenue
Genmark Diagnostics Inc 's Revenue in the fiscal year 2020 $ 171.55 millions
Genmark Diagnostics Inc 's Revenue in the fiscal year 2019 $ 88.02 millions
Genmark Diagnostics Inc 's Revenue in the fiscal year 2017 $ 70.76 millions
Genmark Diagnostics Inc 's Revenue in the fiscal year 2015 $ 49.27 millions
Genmark Diagnostics Inc 's Revenue in the fiscal year 2014 $ 30.59 millions




GNMK Revenue fourth quarter 2020 Y/Y Growth Comment
Genmark Diagnostics Inc achieved in the fourth quarter 2020, above Company average Revenue rise of 84.12% year on year, to $ 50.08 millions.

Looking into fourth quarter 2020 results within Medical Equipment & Supplies industry 13 other companies have achieved higher Revenue growth. While Genmark Diagnostics Inc ' s Revenue jump of 84.12% ranks overall at the positon no. 323 in the fourth quarter 2020.


GNMK Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December 84.12 % 40.35 % 20.97 % 7.59 %
3rd Quarter September 103.87 % 32.41 % 36.21 % 7.31 %
2nd Quarter June 118.24 % 22.96 % 20.87 % -1.2 %
1st Quarter March 79.93 % 4.26 % 64.67 % 13.38 %
FY   94.91 % 24.37 % 34.75 % -

Financial Statements
Genmark Diagnostics Inc 's fourth quarter 2020 Revenue $ 50.08 millions GNMK's Income Statement
Genmark Diagnostics Inc 's fourth quarter 2019 Revenue $ 27.20 millions Quarterly GNMK's Income Statement


GNMK Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December 17.42 % 30.02 % 22.66 % 38.1 %
3rd Quarter September 6.39 % 13.88 % 5.76 % -6.15 %
2nd Quarter June 3.48 % -14.68 % -27.65 % -1.44 %
1st Quarter March 42.43 % 11.09 % 28.9 % -15.78 %
FY (Year on Year)   94.91 % 24.37 % 34.75 % -


Back to GNMK Growth rate Comparisons >> Back to GNMK Growth rate Comparisons >>


Revenue fourth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #14
Healthcare Sector #102
Overall #323

Revenue Y/Y Growth Statistics
High Average Low
414.17 % 39.86 % -100 %
(Mar 31 2013)   (Dec 31 2015)
Revenue fourth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #14
Healthcare Sector #102
Overall #323
Revenue Y/Y Growth Statistics
High Average Low
414.17 % 39.86 % -100 %
(Mar 31 2013)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Genmark Diagnostics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
79.64 % 9.52 % -100 %
(Dec 31 2012)  


GNMK's IV. Quarter Q/Q Revenue Comment
Genmark Diagnostics Inc achieved in the IV. Quarter 2020 above company average sequential Revenue jump of 17.42%, to $ 50.08 millions, from $42.65 millions in the third quarter.

Within Medical Equipment & Supplies industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Genmark Diagnostics Inc 's Revenue growth quarter on quarter, overall rank is 921.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #44
Healthcare Sector #183
Overall #921
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #44
Healthcare Sector #183
Overall #921
Revenue Q/Q Growth Statistics
High Average Low
79.64 % 9.52 % -100 %
(Dec 31 2012)  


GNMK's IV. Quarter Q/Q Revenue Comment
Genmark Diagnostics Inc achieved in the IV. Quarter 2020 above company average sequential Revenue jump of 17.42%, to $ 50.08 millions, from $42.65 millions in the third quarter.

Within Medical Equipment & Supplies industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Genmark Diagnostics Inc 's Revenue growth quarter on quarter, overall rank is 921.


Genmark Diagnostics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)
Cumulative Revenue 12 Months Ending $ 171.55 $ 148.67 $ 126.94 $ 105.23 $ 88.02
Y / Y Revenue Growth (TTM) 94.9 % 85.37 % 69.08 % 46.87 % 24.4 %
Year on Year Revenue Growth Overall Ranking # 624 # 226 # 72 # 38 # 455
Seqeuential Revenue Change (TTM) 15.39 % 17.12 % 20.63 % 19.55 % 9.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 1083 # 277 # 26 # 189 # 1345


Cumulative Revenue growth Comment
With 94.9% annual Revenue growth, Genmark Diagnostics Inc would report a record annual Revenue growth if the fiscal year would end on Dec 31 2020.

In the Healthcare sector 160 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 226 to 624.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 44
Healthcare Sector # 161
Overall # 624

Revenue TTM Y/Y Growth Statistics
High Average Low
94.9 %
 24.88 %
-46.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 44
Sector # 209
S&P 500 # 1083
Cumulative Revenue growth Comment
With 94.9% annual Revenue growth, Genmark Diagnostics Inc would report a record annual Revenue growth if the fiscal year would end on Dec 31 2020.

In the Healthcare sector 160 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 226 to 624.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 44
Healthcare Sector # 161
Overall # 624

Revenue TTM Y/Y Growth Statistics
High Average Low
94.9 %
24.88 %
-46.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 44
Sector # 209
S&P 500 # 1083




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GNMK's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Dec 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2020
Teladoc Health Inc 144.95%$ 144.951 millions
Polarityte Inc 144.88%$ 144.884 millions
Outset Medical Inc 143.43%$ 143.430 millions
Immunitybio inc 133.33%$ 133.333 millions
Adapthealth Corp 133.00%$ 132.999 millions
Seres Therapeutics Inc 130.44%$ 130.438 millions
Interpace Biosciences Inc 128.83%$ 128.826 millions
Alnylam Pharmaceuticals Inc 128.18%$ 128.180 millions
Protagonist Therapeutics inc 127.09%$ 127.090 millions
Halozyme Therapeutics Inc 126.78%$ 126.783 millions
Pandion Therapeutics Inc 126.58%$ 126.577 millions
Cormedix Inc 124.93%$ 124.925 millions
Ibio inc 124.52%$ 124.522 millions
Trevena inc 122.58%$ 122.581 millions
Sanuwave Health Inc 122.29%$ 122.290 millions
Opko Health Inc 120.50%$ 120.499 millions
Oncternal Therapeutics Inc 115.90%$ 115.897 millions
Korro Bio Inc 111.30%$ 111.298 millions
Macrogenics Inc 109.16%$ 109.158 millions
Sinovac Biotech Ltd107.53%$ 107.526 millions
Seagen Inc 107.48%$ 107.483 millions
Adaptimmune Therapeutics Plc106.32%$ 106.319 millions
Cidara Therapeutics Inc 105.45%$ 105.455 millions
Horizon Therapeutics Public Limited Company105.01%$ 105.013 millions
Ensign Group Inc102.16%$ 102.161 millions
Cytomx Therapeutics Inc 97.77%$ 97.765 millions
Meridian Bioscience Inc 95.94%$ 95.941 millions
Epizyme Inc.95.04%$ 95.040 millions
Vivani Medical Inc 94.37%$ 94.366 millions
Karyopharm Therapeutics Inc 93.97%$ 93.966 millions


About Genmark Diagnostics Inc Revenue Growth Rates (GNMK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.